Lorglumide

(Synonyms: CR-1409)

Lorglumide (CR-1409) is an orally active Cholecystokinin Receptor antagonist. Lorglumide inhibits pancreatic cancer cell proliferation, induces G0/G1 phase arrest and apoptosis, and downregulates MMP-2. Lorglumide inhibits gastrin-stimulated Ornithine decarboxylase activity and DNA synthesis, and shows low CCKA/CCKB selectivity. Lorglumide blocks Caerulein (HY-A0190)-induced exocrine pancreatic secretion and pancreatic tissue hyperplastic changes in rats, and inhibits gallbladder emptying induced by exogenous and endogenous CCK in mice. Lorglumide can be used in research related to pancreatic cancer and pancreatic exocrine function.

For research use only. We do not sell to patients.

  • CAS No.: 97964-56-2
  • Formula: C22H32Cl2N2O4
  • Molecular Weight:459.41
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs

All Cholecystokinin Receptor Isoforms

More
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00